Jubilant Pharma Holdings's latest lobbying report covers Q2 2026, at $120K. Its first report covers Q1 2026; the issues it reports most are Trade (Domestic & Foreign).

Jubilant Pharma Holdings

Latest quarter: $120K; Q2 2026 · 1 reports
Last 12 months: $160K; Last 2 quarters
vs last quarter: +200.0%; Q2 2026 against the quarter before
First report: Q1 2026; The first quarter a report named it

Lobbying by quarter

Policy issues the reports name

Trade2 reports

A report that names several issues counts once for each.

Who was lobbied

Food & Drug Administration (FDA)1 reports
HOUSE OF REPRESENTATIVES1 reports

Firms it paid

Firm
Ballard Partners	$160K	2 quarters

Former officials lobbying for it

	Former position	Firm
DANIEL MCFAUL	Legislative Director to U.S. Representative Joe Scarborough; Chief of Staff to U.S. Representatives Jeff Miller and Matt Gaetz.	Ballard Partners	Q2 2026
HUNTER MORGEN	Policy Advisor, Office of Policy Planning, U.S. State Dept. (2017); Deputy Director, Office of Trade & Manufacturing Policy, WH (2017-2018); Special Assistant to the President, Office of the Senior Advisor for Policy, WH (2018-2020)	Ballard Partners	Q1 2026

Lobbying reports

	Filed by		Issues
07/15for Q2	Ballard Partners	$120K	Trade
04/15for Q1	Ballard Partners	$40K	Trade
02/27for Q1	Ballard Partners	Under $5,000	Trade